Emerging Company Profile
Prime Medicine: adding versatility to gene editing
Emerging Company Profile: David Liu’s latest gene editing play is developing a next-generation platform to rewrite DNA
Co-founded by David Liu, Prime Medicine is developing a next-generation gene editing technology that makes more types of genetic alterations without the off-target concerns.
CRISPR-Cas9 gene editing has only started to scratch the surface of its clinical potential, but next-generation iterations including prime editing from new company Prime aren’t far behind.
Prime Medicine Inc. launched on Tuesday with $315 million in funding and a CRISPR-based technology that adds flexibility